Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24week analysis (RIDAR study)
BackgroundThe objective was to analyze the effectiveness and safety of dual therapy with rilpivirine plus boosted-darunavir (RPV+bDRV) in real-life patients.MethodsObservational, retrospective, multi-center study in HIV+ patients who had received RPV+bDRV for 24weeks to optimize/simplify their previ...
| Autores: | , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | INCLIVA |
| Repositorio: | r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| OAI Identifier: | oai:incliva.fundanetsuite.com:p3702 |
| Acceso en línea: | https://incliva.portalinvestigacion.com/publicaciones/3702 |
| Access Level: | acceso abierto |
| Palabra clave: | HIV Simplification Dual therapy Rilpivirine Darunavir Nuke-sparing regimens |
| Sumario: | BackgroundThe objective was to analyze the effectiveness and safety of dual therapy with rilpivirine plus boosted-darunavir (RPV+bDRV) in real-life patients.MethodsObservational, retrospective, multi-center study in HIV+ patients who had received RPV+bDRV for 24weeks to optimize/simplify their previous antiretroviral treatment. We determined the percentage of patients without virologic failure (2 consecutive viral loads >50 copies/mL) at 24weeks of treatment.ResultsThe study included 161 patients from 15 hospitals with median age of 49years; 29.3% had previous AIDS stage and median CD4+ lymphocyte nadir of 170 cells/uL. They had been diagnosed with HIV for a median of 17years and had received 14years of ART, with five previous treatment combinations, and 36.6% had a history of virological failure. The reasons for the switch were simplification/optimization (49.7%), toxicity/intolerance (17.4%), or inadequate effectiveness of previous ART (10.6%).Baseline VL of 50-1000 copies/mL was recorded in 25.5% of the patients. In theintention-to-treat analysis at 24weeks, 87.6% of 161 patients continued the study treatment without virologic failure criteria.In the on treatment analysis (excluding patients who discontinued treatment with dual therapy for any reason other than virologic failure) the efficacy was 94.6% (141/149 patients).ConclusionsDual therapy with RPV+DRVb proved to be effective and safe in patients with advanced HIV infection, long exposure to ART, low CD4 nadir, previous virologic failure, and/or history of ineffective ART. |
|---|